Bro S, Brandi L, Olgaard K
Department of Nephrology P, Rigshospitalet, University of Copenhagen, Denmark.
Nephrol Dial Transplant. 1996;11 Suppl 3:47-9. doi: 10.1093/ndt/11.supp3.47.
A comparison of (i) levels of plasma ionized calcium (Ca), phosphate (P) and iPTH, (ii) risk of hypercalcaemia and (iii) need for Al-containing P binders, in patients on CAPD treated with calcium carbonate as the main P binder and twice weekly oral doses of alfacalcidol for control of secondary hyperparathyroidism during a 1 year follow-up after switching from a dialysis fluid with a Ca concentration of 1.75 mmol/l to 1.25 mmol/l (n = 39) or 1.35 mmol/l (n = 37).
In both groups, a significant initial increase of iPTH was seen. However, iPTH was again suppressed to baseline levels after 2-6 weeks of treatment. No statistically significant difference was observed between the two groups. In both groups median PTH levels were kept below 2.5 times the upper normal limit for non-uraemic patients; median P concentrations below 1.80 mmol/l and median iCa levels within 1.25-1.30 mmol/l. The incidence of hypercalcaemia was low and did not differ between the two groups (1.04 vs 1.20 cases of plasma iCa > 1.45 mmol/l per 100 treatment weeks). The proportion of patients requiring treatment with Al-containing P binders was unchanged from the start to the end of the study period, but significantly greater in the group dialysed with a Ca concentration of 1.25 mmol/l (an average of 21% as compared to 10% in the other group).
When changing from high Ca dialysate (1.75 mmol/l) to dialysate with a Ca concentration of 1.25 or 1.35 mmol/l, close attention to PTH control has to be paid during the initial months of treatment. Adequate control of plasma levels of iCa, P and PTH could be achieved with both lower Ca dialysates without either hypercalcemia or use of Al-containing P binders in the majority of patients. The small number of patients treated with Al-containing P binders, however, would probably benefit from dialysis fluids with even lower Ca concentrations.
比较以碳酸钙作为主要磷结合剂并每周口服两次阿法骨化醇以控制继发性甲状旁腺功能亢进的持续性非卧床腹膜透析(CAPD)患者,在从钙浓度为1.75 mmol/l的透析液转换为1.25 mmol/l(n = 39)或1.35 mmol/l(n = 37)的透析液后的1年随访期间,(i)血浆离子钙(Ca)、磷(P)和全段甲状旁腺激素(iPTH)水平,(ii)高钙血症风险,以及(iii)含铝磷结合剂的使用需求。
两组患者的iPTH均在初始阶段显著升高。然而,治疗2 - 6周后iPTH再次降至基线水平。两组之间未观察到统计学上的显著差异。两组患者的甲状旁腺激素(PTH)中位数均保持在非尿毒症患者正常上限的2.5倍以下;磷(P)中位数低于1.80 mmol/l,离子钙(iCa)中位数在1.25 - 1.30 mmol/l之间。高钙血症的发生率较低,两组之间无差异(每100个治疗周血浆iCa > 1.45 mmol/l的病例数分别为1.04和1.20)。从研究开始到结束,需要使用含铝磷结合剂治疗的患者比例没有变化,但在使用钙浓度为1.25 mmol/l透析液的组中显著更高(平均为21%,而另一组为10%)。
从高钙透析液(1.75 mmol/l)转换为钙浓度为1.25或1.35 mmol/l的透析液时,在治疗的最初几个月必须密切关注PTH的控制。使用较低钙浓度的透析液,大多数患者能够实现血浆iCa、P和PTH水平的充分控制,且不会出现高钙血症或使用含铝磷结合剂。然而,少数使用含铝磷结合剂治疗的患者可能会从钙浓度更低的透析液中获益。